Breast Cancer Subtypes and Survival in Patients with Brain Metastases
Author Information
Author(s): Nam Byung-Ho, Kim Sun Young, Han Hye-Sook, Kwon Youngmee, Lee Keun Seok, Kim Tae Hyun, Ro Jungsil
Primary Institution: National Cancer Center
Hypothesis
The outcome of brain metastases (BM) patients is affected by the specific breast cancer intrinsic subtype.
Conclusion
MBC patients who developed BM had higher proportions of triple-negative and HER2+/ER- tumor status.
Supporting Evidence
- Patients with luminal A tumors had a median survival of 39.6 months.
- Triple-negative tumors had a median survival of 15.5 months.
- HER2+/ER- tumors had a median survival of 20.9 months.
- Older age and presence of leptomeningeal disease were poor prognostic factors.
Takeaway
This study found that certain types of breast cancer are more likely to spread to the brain and that these types have different survival rates.
Methodology
Retrospective survival analyses were performed on 126 BM patients from 805 MBC patients treated at the National Cancer Center.
Potential Biases
Potential selection biases based on clinical and social circumstances.
Limitations
The study is retrospective and may have selection biases.
Participant Demographics
Patients with brain metastases from metastatic breast cancer, median age 47 years.
Statistical Information
P-Value
p = 0.0246
Statistical Significance
p < 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website